Generation of a hypomorphic model of propionic acidemia amenable to gene therapy testing

Adam J. Guenzel, Sean E. Hofherr, Matthew Hillestad, Mary Barry, Eric A Weaver, Sarah Venezia, Jan P. Kraus, Dietrich Matern, Michael A. Barry

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Propionic acidemia (PA) is a recessive genetic disease that results in an inability to metabolize certain amino acids and odd-chain fatty acids. Current treatment involves restricting consumption of these substrates or liver transplantation. Deletion of the Pcca gene in mice mimics the most severe forms of the human disease. Pcca - mice die within 36 hours of birth, making it difficult to test intravenous systemic therapies in them. We generated an adult hypomorphic model of PA in Pcca - mice using a transgene bearing an A138T mutant of the human PCCA protein. Pcca -/- (A138T) mice have 2% of wild-type PCC activity, survive to adulthood, and have elevations in propionyl-carnitine, methylcitrate, glycine, alanine, lysine, ammonia, and markers associated with cardiomyopathy similar to those in patients with PA. This adult model allowed gene therapy testing by intravenous injection with adenovirus serotype 5 (Ad5) and adeno-associated virus 2/8 (AAV8) vectors. Ad5-mediated more rapid increases in PCCA protein and propionyl-CoA carboxylase (PCC) activity in the liver than AAV8 and both vectors reduced propionylcarnitine and methylcitrate levels. Phenotypic correction was transient with first generation Ad whereas AAV8-mediated long-lasting effects. These data suggest that this PA model may be a useful platform for optimizing systemic intravenous therapies for PA.

Original languageEnglish (US)
Pages (from-to)1316-1323
Number of pages8
JournalMolecular Therapy
Volume21
Issue number7
DOIs
StatePublished - Jan 1 2013

Fingerprint

Propionic Acidemia
Genetic Therapy
Dependovirus
Methylmalonyl-CoA Decarboxylase
propionylcarnitine
Adenoviridae
Inborn Genetic Diseases
Gene Deletion
Transgenes
Cardiomyopathies
Ammonia
Intravenous Injections
Alanine
Liver Transplantation
Lysine
Proteins
Fatty Acids
Therapeutics
Parturition
Amino Acids

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Guenzel, A. J., Hofherr, S. E., Hillestad, M., Barry, M., Weaver, E. A., Venezia, S., ... Barry, M. A. (2013). Generation of a hypomorphic model of propionic acidemia amenable to gene therapy testing. Molecular Therapy, 21(7), 1316-1323. https://doi.org/10.1038/mt.2013.68

Generation of a hypomorphic model of propionic acidemia amenable to gene therapy testing. / Guenzel, Adam J.; Hofherr, Sean E.; Hillestad, Matthew; Barry, Mary; Weaver, Eric A; Venezia, Sarah; Kraus, Jan P.; Matern, Dietrich; Barry, Michael A.

In: Molecular Therapy, Vol. 21, No. 7, 01.01.2013, p. 1316-1323.

Research output: Contribution to journalArticle

Guenzel, AJ, Hofherr, SE, Hillestad, M, Barry, M, Weaver, EA, Venezia, S, Kraus, JP, Matern, D & Barry, MA 2013, 'Generation of a hypomorphic model of propionic acidemia amenable to gene therapy testing', Molecular Therapy, vol. 21, no. 7, pp. 1316-1323. https://doi.org/10.1038/mt.2013.68
Guenzel, Adam J. ; Hofherr, Sean E. ; Hillestad, Matthew ; Barry, Mary ; Weaver, Eric A ; Venezia, Sarah ; Kraus, Jan P. ; Matern, Dietrich ; Barry, Michael A. / Generation of a hypomorphic model of propionic acidemia amenable to gene therapy testing. In: Molecular Therapy. 2013 ; Vol. 21, No. 7. pp. 1316-1323.
@article{26036b59621348c9ac9360c892253732,
title = "Generation of a hypomorphic model of propionic acidemia amenable to gene therapy testing",
abstract = "Propionic acidemia (PA) is a recessive genetic disease that results in an inability to metabolize certain amino acids and odd-chain fatty acids. Current treatment involves restricting consumption of these substrates or liver transplantation. Deletion of the Pcca gene in mice mimics the most severe forms of the human disease. Pcca - mice die within 36 hours of birth, making it difficult to test intravenous systemic therapies in them. We generated an adult hypomorphic model of PA in Pcca - mice using a transgene bearing an A138T mutant of the human PCCA protein. Pcca -/- (A138T) mice have 2{\%} of wild-type PCC activity, survive to adulthood, and have elevations in propionyl-carnitine, methylcitrate, glycine, alanine, lysine, ammonia, and markers associated with cardiomyopathy similar to those in patients with PA. This adult model allowed gene therapy testing by intravenous injection with adenovirus serotype 5 (Ad5) and adeno-associated virus 2/8 (AAV8) vectors. Ad5-mediated more rapid increases in PCCA protein and propionyl-CoA carboxylase (PCC) activity in the liver than AAV8 and both vectors reduced propionylcarnitine and methylcitrate levels. Phenotypic correction was transient with first generation Ad whereas AAV8-mediated long-lasting effects. These data suggest that this PA model may be a useful platform for optimizing systemic intravenous therapies for PA.",
author = "Guenzel, {Adam J.} and Hofherr, {Sean E.} and Matthew Hillestad and Mary Barry and Weaver, {Eric A} and Sarah Venezia and Kraus, {Jan P.} and Dietrich Matern and Barry, {Michael A.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1038/mt.2013.68",
language = "English (US)",
volume = "21",
pages = "1316--1323",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Generation of a hypomorphic model of propionic acidemia amenable to gene therapy testing

AU - Guenzel, Adam J.

AU - Hofherr, Sean E.

AU - Hillestad, Matthew

AU - Barry, Mary

AU - Weaver, Eric A

AU - Venezia, Sarah

AU - Kraus, Jan P.

AU - Matern, Dietrich

AU - Barry, Michael A.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Propionic acidemia (PA) is a recessive genetic disease that results in an inability to metabolize certain amino acids and odd-chain fatty acids. Current treatment involves restricting consumption of these substrates or liver transplantation. Deletion of the Pcca gene in mice mimics the most severe forms of the human disease. Pcca - mice die within 36 hours of birth, making it difficult to test intravenous systemic therapies in them. We generated an adult hypomorphic model of PA in Pcca - mice using a transgene bearing an A138T mutant of the human PCCA protein. Pcca -/- (A138T) mice have 2% of wild-type PCC activity, survive to adulthood, and have elevations in propionyl-carnitine, methylcitrate, glycine, alanine, lysine, ammonia, and markers associated with cardiomyopathy similar to those in patients with PA. This adult model allowed gene therapy testing by intravenous injection with adenovirus serotype 5 (Ad5) and adeno-associated virus 2/8 (AAV8) vectors. Ad5-mediated more rapid increases in PCCA protein and propionyl-CoA carboxylase (PCC) activity in the liver than AAV8 and both vectors reduced propionylcarnitine and methylcitrate levels. Phenotypic correction was transient with first generation Ad whereas AAV8-mediated long-lasting effects. These data suggest that this PA model may be a useful platform for optimizing systemic intravenous therapies for PA.

AB - Propionic acidemia (PA) is a recessive genetic disease that results in an inability to metabolize certain amino acids and odd-chain fatty acids. Current treatment involves restricting consumption of these substrates or liver transplantation. Deletion of the Pcca gene in mice mimics the most severe forms of the human disease. Pcca - mice die within 36 hours of birth, making it difficult to test intravenous systemic therapies in them. We generated an adult hypomorphic model of PA in Pcca - mice using a transgene bearing an A138T mutant of the human PCCA protein. Pcca -/- (A138T) mice have 2% of wild-type PCC activity, survive to adulthood, and have elevations in propionyl-carnitine, methylcitrate, glycine, alanine, lysine, ammonia, and markers associated with cardiomyopathy similar to those in patients with PA. This adult model allowed gene therapy testing by intravenous injection with adenovirus serotype 5 (Ad5) and adeno-associated virus 2/8 (AAV8) vectors. Ad5-mediated more rapid increases in PCCA protein and propionyl-CoA carboxylase (PCC) activity in the liver than AAV8 and both vectors reduced propionylcarnitine and methylcitrate levels. Phenotypic correction was transient with first generation Ad whereas AAV8-mediated long-lasting effects. These data suggest that this PA model may be a useful platform for optimizing systemic intravenous therapies for PA.

UR - http://www.scopus.com/inward/record.url?scp=84879692797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879692797&partnerID=8YFLogxK

U2 - 10.1038/mt.2013.68

DO - 10.1038/mt.2013.68

M3 - Article

VL - 21

SP - 1316

EP - 1323

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 7

ER -